Company profile

Handa Neuroscience, LLC

Privately held: no public share price (Handa's corporate history identifies Handa Neuroscience as the Tascenso ODT developer and records its exclusive US commercialization licence to Cycle Pharmaceuticals. Sources: https://handapharma.com.tw/about-en/history/ ; https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214962Orig2s000Approv.pdf Entity resolved by asset-pipeline-v2.)

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Tascenso ODT(Tascenso ODT)
Approved
S1P receptorSmall molecule
Multiple Sclerosis

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.